US Pharma MarketingThe post FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial appeared first on Clinical Trials Arena.
FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial
REGENXBIO has reported that the US FDA has placed a clinical hold on its investigational gene therapy, RGX-121, developed for the treatment of MPS II. The post FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial appeared first on Clinical Trials Arena .
REGENXBIO has reported that the US FDA has placed a clinical hold on its investigational gene therapy, RGX-121, developed for the treatment of MPS II.
Source: Clinical Trials Arena